Novel protein markers of androgen activity in humans: proteomic study of plasma from young chemically castrated men

Abstract

Background:

Reliable biomarkers of androgen activity in humans are lacking. The aim of this study was, therefore, to identify new protein markers of biological androgen activity and test their predictive value in relation to low vs. normal testosterone values and some androgen deficiency linked pathologies.

Methods:

Blood samples from 30 healthy GnRH-antagonist treated males were collected at three time points: a) before GnRH antagonist administration; b) 3 weeks later, just before testosterone undecanoate injection, and c) after additional 2 weeks. Subsequently they were analysed by mass spectrometry to identify potential protein biomarkers of testosterone activity. Levels of proteins most significantly associated with testosterone fluctuations were further tested in a cohort of 75 hypo- and eugonadal males suffering from infertility. Associations between levels of those markers and cardio-metabolic parameters, bone mineral density as well as androgen receptor CAG repeat lengths, were explored.

Results:

Using ROC analysis, 4-hydroxyphenylpyruvate dioxygenase (4HPPD), insulin-like growth factor-binding protein 6 (IGFBP6) and fructose-bisphosphate aldolase (ALDOB), as well as a Multi Marker Algorithm, based on levels of 4HPPD and IGFBP6, were shown to be best predictors of low (< 8 nmol/L) vs. normal (> 12 nmol/L) testosterone. They were also more strongly associated with metabolic syndrome and diabetes than testosterone levels. Levels of ALDOB and 4HPPD levels also showed association with AR CAG-repeat lengths.

Conclusions:

We identified potential new protein biomarkers of testosterone action. Further investigations to elucidate their clinical potential are warranted.

Funding:

The work was supported by ReproUnion 2.0 (grant no 20201846), which is funded by the Interreg V EU program.

Data availability

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (60) partner repository with the dataset identifier PXD024448.Supplementary tables (datasets):https://doi.org/10.6084/m9.figshare.14875431Source data of the Figures can be found on:https://doi.org/10.6084/m9.figshare.14875431Supplementary Figure S1 (Figure 2-figure supplement 1):https://doi.org/10.6084/m9.figshare.14876562

The following data sets were generated

Article and author information

Author details

  1. Aleksander Giwercman

    Department of Translational Medicine, Lund University, Malmo, Sweden
    For correspondence
    aleksander.giwercman@med.lu.se
    Competing interests
    Aleksander Giwercman, received consulting fees from Besins Healthcare. The author has no other competing interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5816-0785
  2. K Barbara Sahlin

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  3. Indira Pla Parada

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  4. Krzysztof Pawlowski

    Department of Experimental Design and Bioinformatics, Warsaw University of Life Sciences, Warszawa, Poland
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5367-0935
  5. Carl Fehninger

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0922-7749
  6. Yvonne Lundberg Giwercman

    Department of Translational Medicine, Lund University, Malmo, Sweden
    Competing interests
    No competing interests declared.
  7. Irene Leijonhufvud

    Department of Translational Medicine, Lund University, Malmo, Sweden
    Competing interests
    No competing interests declared.
  8. Roger Appelqvist

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  9. György Marko-Varga

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  10. Aniel Sanchez

    Department of Biomedical Engineering, Lund University, Lund, Sweden
    Competing interests
    No competing interests declared.
  11. Johan Malm

    Department of Translational Medicine, Lund University, Malmo, Sweden
    Competing interests
    No competing interests declared.

Funding

ReproUnion (20201846)

  • Aleksander Giwercman

Swedish Governmental Fund for Clinical Research

  • Aleksander Giwercman

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: All subjects were enrolled with informed written consent. The two studies from which they were recruited were approved by the Swedish Ethical Review Authority (Approval number: DNR 2014/311, date of approval 8 May 2014; DNR 2011/1, date of approval 11 January 2011).

Copyright

© 2022, Giwercman et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 976
    views
  • 165
    downloads
  • 5
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Aleksander Giwercman
  2. K Barbara Sahlin
  3. Indira Pla Parada
  4. Krzysztof Pawlowski
  5. Carl Fehninger
  6. Yvonne Lundberg Giwercman
  7. Irene Leijonhufvud
  8. Roger Appelqvist
  9. György Marko-Varga
  10. Aniel Sanchez
  11. Johan Malm
(2022)
Novel protein markers of androgen activity in humans: proteomic study of plasma from young chemically castrated men
eLife 11:e74638.
https://doi.org/10.7554/eLife.74638

Share this article

https://doi.org/10.7554/eLife.74638

Further reading

    1. Medicine
    2. Neuroscience
    Joanna Kosinska, Julian C Assmann ... Markus Schwaninger
    Research Article

    Monomethyl fumarate (MMF) and its prodrug dimethyl fumarate (DMF) are currently the most widely used agents for the treatment of multiple sclerosis (MS). However, not all patients benefit from DMF. We hypothesized that the variable response of patients may be due to their diet. In support of this hypothesis, mice subjected to experimental autoimmune encephalomyelitis (EAE), a model of MS, did not benefit from DMF treatment when fed a lauric acid-rich (LA) diet. Mice on normal chow (NC) diet, in contrast, and even more so mice on high-fiber (HFb) diet showed the expected protective DMF effect. DMF lacked efficacy in the LA diet-fed group despite similar resorption and preserved effects on plasma lipids. When mice were fed the permissive HFb diet, the protective effect of DMF treatment depended on hydroxycarboxylic receptor 2 (HCAR2) which is highly expressed in neutrophil granulocytes. Indeed, deletion of Hcar2 in neutrophils abrogated DMF protective effects in EAE. Diet had a profound effect on the transcriptional profile of neutrophils and modulated their response to MMF. In summary, DMF required HCAR2 on neutrophils as well as permissive dietary effects for its therapeutic action. Translating the dietary intervention into the clinic may improve MS therapy.

    1. Medicine
    Hyun Beom Song, Laura Campello ... Anand Swaroop
    Research Advance

    Inherited retinal degenerations (IRDs) constitute a group of clinically and genetically diverse vision-impairing disorders. Retinitis pigmentosa (RP), the most common form of IRD, is characterized by gradual dysfunction and degeneration of rod photoreceptors, followed by the loss of cone photoreceptors. Recently, we identified reserpine as a lead molecule for maintaining rod survival in mouse and human retinal organoids as well as in the rd16 mouse, which phenocopy Leber congenital amaurosis caused by mutations in the cilia-centrosomal gene CEP290 (Chen et al., 2023). Here, we show the therapeutic potential of reserpine in a rhodopsin P23H rat model of autosomal dominant RP. At postnatal day (P) 68, when males and females are analyzed together, the reserpine-treated rats exhibit higher rod-derived scotopic b-wave amplitudes compared to the controls with little or no change in scotopic a-wave or cone-derived photopic b-wave. Interestingly, the reserpine-treated female rats display enhanced scotopic a- and b-waves and photopic b-wave responses at P68, along with a better contrast threshold and increased outer nuclear layer thickness. The female rats demonstrate better preservation of both rod and cone photoreceptors following reserpine treatment. Retinal transcriptome analysis reveals sex-specific responses to reserpine, with significant upregulation of phototransduction genes and proteostasis-related pathways, and notably, genes associated with stress response. This study builds upon our previously reported results reaffirming the potential of reserpine for gene-agnostic treatment of IRDs and emphasizes the importance of biological sex in retinal disease research and therapy development.